Bridger Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bridger Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,800	Closed	-$2.53M	–	36
2023 Q2	$2.53M	Hold	24,800	–	–	0.84%	25
2023 Q1	$2.25M	Buy	+24,800	New	+$1.46M	0.84%	21

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bridger Management's RETA Position: Q3 2023 in Review

Bridger Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 24,800 shares — an estimated $2.53M sold.

Bridger Management first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $2.53M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Bridger Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Bridger Management sold 24,800 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.53M.
Bridger Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Bridger Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.53M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Bridger Management's 13F filing for Q3 2023, filed 14 Nov 2023.